teladoc health inc posted a sizable net loss for its latest quarter after taking more impairment charges and it delivered a firstquarter forecast that trailed the consensus view shares of teladoc tdoc were off more than 7 in afterhours trading wednesday following its earnings report the company logged a net loss of 38 billion or 2349 a share compared with a loss of 109 million or 7 cents a share in the yearearlier quarter analysts tracked by factset were expecting a 25cent loss per share teladoc recorded 38 billion in impairment charges during the quarter building on charges taken earlier in the year taken into account that goodwill impairment the company reported a net loss of 137 billion for 2022 teladoc recorded fourthquarter adjusted earnings before interest taxes depreciation and amortization ebitda of 94 million up from 77 million a year before while the factset consensus was for 92 million revenue rose to 638 million from 554 million a year prior and exceeded the factset consensus which was for 633 million “despite a challenging macro environment we were able to expand our product offerings and enhance the level of care delivered across our integrated wholeperson platform” chief executive jason gorevic said in a release the company is “committed to a balanced approach to growth and margin which will allow us to invest in key initiatives across our product roadmap” he added for the first quarter teladoc anticipates 610 million to 625 million in revenue along with 42 million to 50 million in adjusted ebitda analysts tracked by factset were modeling 652 million in revenue and 62 million in adjusted ebitda looking at the full year teladoc expects 2550 billion to 2675 billion in revenue as well as 275 million to 325 million in adjusted ebitda the factset consensus was for 2712 billion in revenue and adjusted ebitda of 297 million shares of teladoc have fallen by more than half over the past year as the sp 500 spx has lost 7